A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Castration-Resistant Prostatic Cancer Clinical Trial

Official title:
A Phase Ib, Open-Label, Multicenter Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer.

Status Terminated

Clinical Trial Summary

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort of approximately 38 participants. All participants in this study will continue to be treated until progression of disease, loss of clinical benefit, unacceptable toxicity or withdrawal of consent.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Castration-Resistant Prostatic Cancer
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

Clinical Trial Details

NCT number	NCT04404140
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Terminated
Phase	Phase 1
Start date	July 9, 2020
Completion date	October 14, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04116164` - Safety and Targeting of Anti-hk2 Antibody in mCRPC	Early Phase 1
Not yet recruiting	`NCT04126915` - Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)
Recruiting	`NCT04104607` - the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma	Phase 1
Recruiting	`NCT03016741` - Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer	Phase 4
Completed	`NCT02398526` - Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Active, not recruiting	`NCT05551117` - A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors	Phase 2
Recruiting	`NCT02998567` - Combination Study of Guadecitabine/ASTX727 and Pembrolizumab	Phase 1
Active, not recruiting	`NCT03748641` - A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer	Phase 3
Recruiting	`NCT05293496` - A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors	Phase 1
Available	`NCT06033001` - Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)